Tumor-suppressing pathways in cystic pancreatic tumors

Pancreas

Volumn 26, Issue 1, 2003, Pages 42-48

  Gerdes, Berthold ^a   Wild, Anja ^a   Wittenberg, Judith ^a   Barth, Peter ^a   Ramaswamy, Annette ^a   Kersting, Michael ^a   Lüttges, Jutta ^b   Klöppel, Günter ^b   Bartsch, Detlef K ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Cystic pancreatic tumors; DPC4; P161NK4a; P53; Tumor suppressing pathways

Indexed keywords

DNA; PROTEIN P16; PROTEIN P53; SMAD4 PROTEIN;

ARTICLE; CLINICAL ARTICLE; DNA METHYLATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUCINOUS CARCINOMA; NUCLEOTIDE SEQUENCE; PANCREAS CYST; PANCREAS TUMOR; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, SEROUS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DNA-BINDING PROTEINS; GENES, P16; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SMAD4 PROTEIN; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037214193     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200301000-00008     Document Type: Article

References (40)

1. Sener SF, Fremgen A, Imperato JP, et al. Pancreatic cancer in Illinois: A report by 88 hospitals on 2,401 patients diagnosed 1978-84. Am Surg 1991;57:490-5.
2. Sessa F, Solcia E, Capella C, et al. Intraductal papillary-mucinous tumors represent a distinct group of pancreatic neoplasms: An investigation of tumor cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch 1994;425:357-67.
3. Kosmahl M, Seada LS, Janig U, et al. Solid-pseudopapillary tumor of the pancreas: Its origin revisited. Virchows Arch 2000;436:473-80.
4. Klöppel G, Kosmahl M. Cystic lesions and neoplasms of the pancreas - The features are becoming clearer. Pancreatology 2001;1:648-55.
5. Bartsch D, Bastian D, Barth P, et al. K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas. Ann Surg 1998;228:79-86.
6. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
7. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: One gene-two products-two pathways. Trends Biochem Sci 1998;23:291-6.
8. Simon B, Weinel R, Hohne M, et al. Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma. Gastroenterology 1994;106:1645-51.
9. Huang L, Goodrow TL, Zhang SY, et al. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 1996;56:1137-41.
10. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
11. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
12. Zhang Y, Feng X, We R, et al. Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature 1996;383:168-72.
13. Solcia E, Capella C, Klöppel G. Tumors of the Pancreas. In: Rosai I, Sobin LH, eds. Bethesda, Maryland: Universities Associated for Research and Education in Pathology, Inc., 1997.
14. Wright DK, Manos MM. Sample preparation from paraffin embedded tissues. In: PCR Protocols: A Guide to Methods and Applications. Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. San Diego: Academic Press, 1990:153-8.
15. Brentnall TA, Chen R, Lee JG, et al. Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res 1995;55:4264-7.
16. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation. Am J Pathol 2000;156:37-43.
17. INK4a alterations in chronic pancreatitis - Indicator for high risk lesions for pancreatic cancer. Surgery 2001;129:490-7.
18. Gerdes B, Bartsch DK, Ramaswamy A, et al. Multiple primary tumors as an indicator for p16INK4a germline mutations in pancreatic cancer patients? Pancreas 2000;21:369-75.
19. Geradts J, Hruban RH, Schutte M, et al. Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. Appl Immunohistochem Mol Morphol 2000;8:71-9.
20. Hu YX, Watanabe H, Ohtsubo K, et al. Frequent loss of p16 expression and its correlation with clinicopathologic parameters in pancreatic carcinoma. Clin Cancer Res 1997;3:1473-7.
21. Higashiyama M, Doi O, Kodama K, et al. MDM2 gene amplification and expression in non-small-cell lung cancer: Immunohistochemical expression of its protein is a favorable prognostic marker in patients without p53 protein accumulation. Br J Cancer 1997;75:1302-8.
22. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002-6.
23. Luttges J, Galehdari H, Bröcker V, et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol 2001;158:1677-83.
24. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
25. Bartsch D, Barth P, Bastian D, et al. Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas. Cancer Lett 1999;139:43-9.
26. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991;253:49-53.
27. Naumann M, Savitskaia N, Eilert C, et al. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 1996;110:1215-24.
28. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-30.
29. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
30. Bartsch D, Shevlin DW, Callery MP, et al. Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation. J Natl Cancer Inst 1996;88:680-2.
31. Kawahira H, Kobayashi S, Kaneko K, et al. p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy. Hepatogastroenterology 2000;47:973-7.
32. Luttges J, Kloppel G. Update on the pathology and genetics of exocrine pancreatic tumors with ductal phenotype: Precursor lesions and new tumor entities. Dig Dis 2001;19:15-23.
33. Flejou JF, Boulange B, Bemades P, et al. p53 protein expression and DNA ploidy in cystic tumors of the pancreas. Pancreas 1996;13:247-52.
34. Zamboni G, Scarpa A, Bogina G, et al. Mucinous cystic tumors of the pancreas: Clinicopathologic features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999;23:410-22.
35. Jimenez RE, Warshaw AL, Z'graggen K, et al. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg 1999;230:501-9.
36. Yamaguchi K, Chijiiwa K, Noshiro H, et al. Ki-ras codon 12 point mutation and p53 mutation in pancreatic diseases. Hepatogastroenterology 1999;46:2575-81.
37. Iacobuzio-Donahue CA, Wilentz RE, Argani P, et al. Dpc4 protein in mucinous cystic neoplasms of the pancreas: Frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol 2000;24:1544-8.
38. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
39. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-41.
40. Moore PS, Zamboni G, Brighenti A, et al. Molecular characterization of pancreatic serous microcystic adenomas: Evidence for a tumor suppressor gene on chromosome 10q. Am J Pathol 2001;158:317-21.